Withdrawal reaction associated with venlafaxine.

Nottingham Healthcare NHS Trust, Wells Road Centre, Nottingham NG3 3AA.
BMJ Clinical Research (Impact Factor: 14.09). 10/1998; 317(7161):787.
Source: PubMed


Available from: Walter P Bouman, Jun 06, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Venlafaxine is an antidepressant that selectively inhibits serotonin reuptake and is a norepinephrine inhibitor. Withdrawal syndromes can occur after abrupt drug discontinuation of long-term regimens. Exegesis We report six cases of withdrawal symptoms after venlafaxine discontinuation. Conclusion Physicians must be aware of the frequency, rapidity and potent severity of these withdrawal syndromes.
    La Revue de Médecine Interne 03/2000; 21(3):282-284. DOI:10.1016/S0248-8663(00)80048-X · 1.32 Impact Factor
  • Acta Psychiatrica Scandinavica 10/2009; 120(4):332-3. DOI:10.1111/j.1600-0447.2009.01430.x · 5.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Venlafaxine is an inhibitor of neuronal serotonin and noradrenaline re-uptake and a weak inhibitor of dopamine re-uptake. There was no indication of problems of abuse/dependence during the clinical trials. A 53-year-old client with a history of alcohol and amineptine misuse and a long history of recurrent depression, for which he was prescribed venlafaxine tablets. Over time, he increased the dosage to 50 tablets daily (3750 mg). Large venlafaxine dosages produced amphetamine-like effects, due possibly to the related increase in dopamine turnover. Once hospitalized for detoxification, the patient had a symptomatology which was consistent with a serotonergic discontinuation syndrome. Physicians should be aware that patients with a history of drug and alcohol abuse might develop venlafaxine dependence.
    Addiction 09/2008; 103(9):1572-4. DOI:10.1111/j.1360-0443.2008.02266.x · 4.60 Impact Factor